Englander Institute for Precision Medicine

Publications

Found 790 results
Author Title Type [ Year(Asc)]
2021
Lan Y, Banks KM, Pan H, Verma N, Dixon GR, Zhou T, Ding B, Elemento O, Chen S, Huangfu D et al..  2021.  Stage-specific regulation of DNA methylation by TET enzymes during human cardiac differentiation.. Cell Rep. 37(10):110095.
Dewhurst SM, Yao X, Rosiene J, Tian H, Behr J, Bosco N, Takai KK, de Lange T, Imielinski M.  2021.  Structural variant evolution after telomere crisis.. Nat Commun. 12(1):2093.
Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T, Tryakin A, Stahl O, Gonzalez-Billalabeitia E, De Giorgi U et al..  2021.  Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.. J Clin Oncol. 39(14):1553-1562.
Aguiar-Pulido V, Wolujewicz P, Martinez-Fundichely A, Elhaik E, Thareja G, Aleem AAbdel, Chalhoub N, Cuykendall T, Al-Zamer J, Lei Y et al..  2021.  Systems biology analysis of human genomes points to key pathways conferring spina bifida risk.. Proc Natl Acad Sci U S A. 118(51)
Vitale I, Yamazaki T, Wennerberg E, Sveinbjørnsson B, Rekdal Ø, Demaria S, Galluzzi L.  2021.  Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides.. Trends Cancer. 7(6):557-572.
Buqué A, Galluzzi L, Montrose DC.  2021.  Targeting Serine in Cancer: Is Two Better Than One? Trends Cancer. 7(8):668-670.
Sugita M, Wilkes DC, Bareja R, Eng KW, Nataraj S, Jimenez-Flores RA, Yan LB, De Leon JPauline, Croyle JA, Kaner J et al..  2021.  Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia.. NPJ Precis Oncol. 5(1):44.
Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, Pakula H, Carelli R, Khani F, Bakht M et al..  2021.  Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.. Nat Commun. 12(1):3372.
Chávez ASOliva, Wang X, Marnin L, Archer NK, Hammond HL, Carroll EEMcClure, Shaw DK, Tully BG, Buskirk AD, Ford SL et al..  2021.  Tick extracellular vesicles enable arthropod feeding and promote distinct outcomes of bacterial infection.. Nat Commun. 12(1):3696.
Rakova J, Truxova I, Holicek P, Salek C, Hensler M, Kasikova L, Pasulka J, Holubova M, Kovar M, Lysak D et al..  2021.  TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients.. Oncoimmunology. 10(1):1889822.
Elemento O.  2021.  Towards artificial intelligence-driven pathology assessment for hematological malignancies.. Blood Cancer Discov. 2(3):195-197.
Humeau J, Le Naour J, Galluzzi L, Kroemer G, Pol JG.  2021.  Trial watch: intratumoral immunotherapy.. Oncoimmunology. 10(1):1984677.
Liu D, Augello MA, Grbesa I, Prandi D, Liu Y, Shoag JE, R Karnes J, Trock BJ, Klein EA, Den RB et al..  2021.  Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.. J Clin Invest. 131(10)
Galassi C, Vitale I, Galluzzi L.  2021.  Using epigenetic modifiers to target cancer stem cell immunoevasion.. Cancer Cell. 39(12):1573-1575.
Zoughbi WAl, Fox J, Beg S, Papp E, Hissong E, Ohara K, Keefer L, Sigouros M, Kane T, Bockelman D et al..  2021.  Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.. Oncologist. 26(11):e1971-e1981.
Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TChedraoui, Wong CK, Choi HYoung, Felau I, A Robertson G et al..  2021.  Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway.. Cell Rep. 34(5):108707.
2020
Casiraghi N, Orlando F, Ciani Y, Xiang J, Sboner A, Elemento O, Attard G, Beltran H, Demichelis F, Romanel A.  2020.  ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA.. Bioinformatics. 36(9):2665-2674.
Palikuqi B, Nguyen D-HT, Li G, Schreiner R, Pellegata AF, Liu Y, Redmond D, Geng F, Lin Y, Gómez-Salinero JM et al..  2020.  Adaptable haemodynamic endothelial cells for organogenesis and tumorigenesis.. Nature. 585(7825):426-432.
Ginter PS, McIntire PJ, Kurtis B, Mirabelli S, Motanagh S, Hoda S, Elemento O, Shin SJ, Mosquera JMiguel.  2020.  Adenomyoepithelial tumors of the breast: molecular underpinnings of a rare entity.. Mod Pathol. 33(9):1764-1772.
Ge Y, Miao Y, Gur-Cohen S, Gomez N, Yang H, Nikolova M, Polak L, Hu Y, Verma A, Elemento O et al..  2020.  The aging skin microenvironment dictates stem cell behavior.. Proc Natl Acad Sci U S A. 117(10):5339-5350.
Antonarakis ES, Velho PIsaacsson, Fu W, Wang H, Agarwal N, Santos VSacristan, Maughan BL, Pili R, Adra N, Sternberg CN et al..  2020.  -Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.. JCO Precis Oncol. 4:370-381.
Rheinbay E, Nielsen MMuhlig, Abascal F, Wala JA, Shapira O, Tiao G, Hornshøj H, Hess JM, Juul RIstrup, Lin Z et al..  2020.  Analyses of non-coding somatic drivers in 2,658 cancer whole genomes.. Nature. 578(7793):102-111.
Armstrong AJ, Al-Adhami M, Lin P, Parli T, Sugg J, Steinberg J, Tombal B, Sternberg CN, de Bono J, Scher HI et al..  2020.  Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.. JAMA Oncol. 6(2):217-225.
Otto L, Budde K, Kastenmüller G, Kaul A, Völker U, Völzke H, Adamski J, Kühn JP, Krumsiek J, Artati A et al..  2020.  Associations between adipose tissue volume and small molecules in plasma and urine among asymptomatic subjects from the general population.. Sci Rep. 10(1):1487.
Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y et al..  2020.  Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.. Nature. 585(7826):E20.